All News

Telemedicine black computer

Can tender and swollen joint counts work in a telemedicine world?

David Liew, FRACP

In a world where telemedicine and virtual care are not going away, is there value in patients assessing their own tender and swollen joints?

Read Article
Back Pain

Bridging the gap in the delayed diagnosis of axSpA

Swetha Ann Alexander, MD

Delay in the diagnosis of axial spondyloarthritis (axSpA) has been a huge challenge and is associated with poor outcomes.

Read Article
Man in window

Sick Leave in axSpA: Who takes more?

Rachel Tate, DO

Who wouldn't like to predict the future? 

Read Article
ACR Best

ACR21 Best Abstracts - Day 1

Jack Cush, MD

The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.

Read Article
Welder

Work participation in patients with axial spondyloarthritis

Mrinalini Dey, MD

Patients with axial spondyloarthritis (axSpA) often have increased absence from work as well as reduced productivity at work, which can have profound impacts for not only the affected individual and their families, but also lead to wider economic and social burden.

Read Article
acr_session2.jpeg

Opening Day Report

Jack Cush, MD

The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).

Read Article
In this study, ⭕AS pts w/>=2 #comorbidities were associated w/ poorer outcome measures after 2 yrs of ffup vs. pts w/ no comorbids ⭕Pts w/ >=2 comorbids were likely to dc 1st anti-TNF Address comorbidities, ⬆ chances of better outcomes & QoL @RheumNow #ACR21 abs1309 https://t.co/sTnjaC1a1l
sheila RHEUMarampa ( View Tweet)
#ACR21 Abs#1225: B/L Extracell Matrix Biomarkers predict ABA response in MTX-naive, +ACPA early RA ⭐️ECM biomarkers predict SDAI remission or DAS28 w ABA+MTX vs PBO+MTX. ⭐️⬆️CTX1 biomarker predicts efficacy endpts for ABA+MTX https://t.co/7wHQefb5D4 @Rheumnow

Links:

Eric Dein ericdeinmd ( View Tweet)

Dr Bass on the ICI M triad: Myositis, Myocarditis, Myasthenia--> Strongly a/w morbidity & mortality ~0.4% frequency, mortality 22% when myositis alone ~Overlap (+ myasthenia or myocarditis) more common w/ combination ICI, mortality 42% #ACR21 #ACRAmbassador https://t.co/g50tzAYhlS
Veena Katikineni VeenaRheumMD ( View Tweet)
Abst#0572: In US veterans w/ RA followed for 17 yrs, several cytokines+chemokines ⭐️Associated w/ ↑ risk of incident MACE independent of typical CVD RF & RA activity & ⭐️Predicted MACE even if in LDA/remission WOW! We need to do better @ CVD risk strat! #ACRBest @RheumNow https://t.co/J74rRa9EQE
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#Abs0588 Effectiveness of TNFi vs non-TNFis in obese patients with #rheumatic disease @MilenaGianfran: 👉🏼>16000pts @ACRheum RISE 👉🏼Abatacept➡️larger decreases in CDAI in obese pts 👉🏼Tocilizumab➡️larger decreases in CDAI in non-obese pts @RheumNow #ACR21 https://t.co/bL5xnG1iNh

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

#ACR21 #Abstr0866 Data from #COVID19 GRA Registry showed predictors of poor COVID outcome in 1922 #lupus pts: Older age Male Areas outside Europe, 🇺🇸🇨🇦 Infection <June 2020 Any Corticosteroid dose Not on therapy On Rituximab Comorbidities ⬆️disease activity @RheumNow #ACRBest https://t.co/u0GF3aDsFA
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Can patient with low dx activity SLE stop HCQ, or at least try and reduce the dose? Not if you want to avoid flares. If there are safer subgroups to try it in, we haven't found them yet (in fact higher dx activity➡️less risk ?other Rx) SLICC inception #ACR21 ABST0959 @RheumNow https://t.co/NS2V4dEGHv
David Liew drdavidliew ( View Tweet)
#ultrasound led to a change in Dx or Tx 2/3 of the time in a Sports Med clinic! #ACR21 #ACRAmbassador #POCUS https://t.co/2CviSOQKiz
Arthur Mandelin, MD/PhD, RhMSUS, RMSK NU_Rheum_MSK_US ( View Tweet)
Dr Blazer sheds light on the multilayered SDOHs as they affect outcomes in chronic diseases. Head over to #ACR21 https://t.co/Jq7aiRV3MD
Chinny Jumai Osuorji,MD MediaRheum ( View Tweet)
Greater #comorbidity burden is assoc. w/ worse improvement and disease activity in 1st yr of treatment in ERA @earlyarthritis. Comorbidities esp affect SJC and patient and physician global assessments. #ACR21 Abs#0798 @RheumNow https://t.co/02BRqYp9Yk

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

#ACR21 Abst#0285 Calculated 10-yr CV risk ↑ w/in 1st yr of new RA dx in 53 Dutch pts: ➤43% had intermediate (I) or high (H) morbidity risk ➤76% had I or H mortality risk ◘ avg 57yo, 74%♀, 72% HTN, & 57% HLD *️⃣ Early CV risk assessment critical at RA diagnosis! @Rheumnow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

#ACR21 #Abstr0437 OK, so RTX affects #COVID vaccine but some pts need RTX. Factors predicting response to vaccine: RA vs AAV/IIM Higher IgG Longer time-to-RTX Lower RTX courses Number. Prediction Calculator is developed but need ext. validation #RheumNow https://t.co/iXSaGQ76hS https://t.co/WQAV3GRPBz

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 #Abstr0261 In stable Non sJIA, is it safe to taper or stop MTX? Of 375 pts in CARRA registry, 24% tapered and 14% stopped MTX. No diff in flare rates btw those continued vs tapered/stopped. Sustained remission was in ⬆️tapered vs stopped @RheumNow https://t.co/Mm1yfzRBQz https://t.co/rkHvXWj2oO

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 Ignaki Sanz makes the case that +++ AUTOANTIBODIES are integrally involved in #COVID19 immunopathogeneisis and may rise and fall w disease states- TBD what role they play in acute disease and #LongCovid @CCalabreseDO @VirusesImmunity @CleClinicMD #COVID19AB https://t.co/9dzCSh5V7R
Leonard Calabrese LCalabreseDO ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×